Protagonist Therapeutics

PTGX · Nasdaq · United States

Share price · PTGX

$127.16-30.18 (-19.18%) 3M

close as of 2026-11-18 · 24h delayed · vol 433K (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PTGX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Aug 2026+6.5%
  2. 17 Jul 2026+6.7%

    Nothing announced by PTGX that day or the session before.

  3. 7 Jul 2026+7.1%

    Nothing announced by PTGX that day or the session before.

  4. 9 Jun 2026+8.0%
  5. 4 Jun 2026+7.7%
  6. 11 May 2026+4.2%

    Nothing announced by PTGX that day or the session before.

  7. 28 Apr 2026+2.7%
  8. 14 Apr 2026+7.3%
  9. 19 Mar 2026+4.7%
  10. 27 Feb 2026+4.2%

Share of unusual movement by asset

For each asset, the share of PTGX's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
icotrokinra (Icotyde)
events and moves
113%
rusfertide
events and moves
5shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—3%
Sessions with no dated event—92%

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
icotrokinra(Icotyde)
Approved
IL-23 receptorPeptide
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis
Ulcerative Colitis, Crohn's Disease
Approved
FerroportinPeptide
Polycythemia Vera

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
February 2027 (1)
icotrokinra · IcotydePhase 3Arthritis, Psoriatic
Est. primary completion 2027-02-10 · NCT06807424 · CT.gov ↗
What to watch
October 2027 (1)
rusfertidePhase 2Polycythemia Vera
Est. primary completion 2027-10-28 · NCT07648030 · CT.gov ↗
What to watch
2028 (3)
January 2028 (1)
icotrokinra · IcotydePhase 3Colitis, Ulcerative
Est. primary completion 2028-01-14 · NCT07196748 · CT.gov ↗
What to watch
July 2028 (1)
rusfertidePhase 2Polycythemia Vera
Est. primary completion 2028-07-01 · NCT07765602 · CT.gov ↗
What to watch
September 2028 (1)
icotrokinra · IcotydePhase 2/3Crohn Disease
Est. primary completion 2028-09-19 · NCT07196722 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(8)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

September 2026ApprovalicotrokinraEuropean Commission approves ICOTYDE in plaque psoriasis
EU, EC · Johnson & Johnson · Source ↗
18 March 2026ApprovalicotrokinraFDA approves ICOTYDE (icotrokinra) for plaque psoriasis
US, FDA · Source ↗
2 March 2026Filing acceptedrusfertideFDA accepts rusfertide NDA
US, FDA · Protagonist Therapeutics · Source ↗
2 March 2026Priority reviewrusfertideRusfertide NDA under Priority Review
US, FDA · Protagonist Therapeutics · Source ↗
21 July 2025Filing submittedicotrokinraNDA submitted for icotrokinra in plaque psoriasis
US, FDA · Source ↗
10 March 2025Topline resulticotrokinraANTHEM-UC Phase 2b topline results
3 March 2025Topline resultrusfertidePhase 3 VERIFY topline
Protagonist Therapeutics · Source ↗
18 November 2024Topline resulticotrokinraICONIC-LEAD Phase 3 topline: co-primary endpoints met
Johnson & Johnson · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$41M$499M+ $302M short-term inv.—-$23M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$42M$420M+ $363M short-term inv.—$219M operating cash flowreport ↗
2026-Q1$56M$47M$194M+ $354M short-term inv.—-$49M operating cash flowreport ↗
2025-Q3$4.7M$40M$114M+ $462M short-term inv.$39M-$1.9M operating cash flowreport ↗
2025-Q2$5.5M$37M$169M+ $402M short-term inv.$35M-$29M operating cash flowreport ↗
2025-Q1$28M$36M$140M+ $435M short-term inv.$12M$125M operating cash flowreport ↗
2024-Q3$4.7M$36M$131M+ $338M short-term inv.$33M-$28M operating cash flowreport ↗
2024-Q2$4.2M$34M$356M+ $208M short-term inv.$31M$269M operating cash flowreport ↗
2024-Q1$255M$34M$173M+ $150M short-term inv.—-$27M operating cash flowreport ↗
2023-Q3$0$31M$231M+ $90M short-term inv.$34M-$27M operating cash flowreport ↗
2023-Q2$0$33M$236M+ $78M short-term inv.$38M-$26M operating cash flowreport ↗
2023-Q1$0$27M$128M+ $103M short-term inv.$34M-$34M operating cash flowreport ↗
2022-Q3$0$25M$153M+ $115M short-term inv.$31M-$25M operating cash flowreport ↗
2022-Q2$0.9M$35M$120M+ $172M short-term inv.$41M-$14M operating cash flowreport ↗
2022-Q1$26M$36M$99M+ $207M short-term inv.$21M-$38M operating cash flowreport ↗
2021-Q3$10M$37M$121M+ $194M short-term inv.$34M-$28M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$46M$159M$129M+ $439M short-term inv.$33M$58M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$434M$138M$97M+ $322M short-term inv.—$184M operating cash flowreport ↗
2023-FY$60M$120M$187M+ $155M short-term inv.$20M-$70M operating cash flowreport ↗
2022-FY$27M$126M$126M+ $112M short-term inv.$32M-$108M operating cash flowreport ↗
2021-FY$27M$126M$124M+ $203M short-term inv.$31M-$108M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 37 sales ($95.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16MOLINA ARTURO MD · Chief Medical OfficerOpen-market sale2,718$124.65$339KForm 4
2026-09-30Ali Asif · Chief Financial OfficerOption exercise9,229$38.98$360KForm 4
2026-09-30Ali Asif · Chief Financial OfficerOption exercise28,438$23.42$666KForm 4
2026-09-30Ali Asif · Chief Financial OfficerOption exercise15,650$19.19$300KForm 4
2026-09-30Ali Asif · Chief Financial OfficerOption exercise5,312$12.17$65KForm 4
2026-09-30Ali Asif · Chief Financial OfficerOpen-market sale12,595$141.77$1.8MForm 4
2026-09-30Ali Asif · Chief Financial OfficerOpen-market sale46,034$141.78$6.5MForm 4
2026-09-30Ali Asif · Chief Financial OfficerOption exercise (derivative)9,229——Form 4